Enzo Biochem, Inc. (NYSE:ENZ) today announced the appointment of Mohan
Chellani, Ph.D., formerly a senior manager with Quest Diagnostics, as
Vice President of Scientific Affairs at its Enzo Clinical Labs
subsidiary. He will oversee all aspects of the Labs’ Molecular
Diagnostic’s strategy and implementation, including serving as a key
interface with Enzo Life Sciences, another Enzo subsidiary.
Enzo Biochem is a biotechnology company specializing in gene
identification and genetic and immune regulation technologies for
diagnostic and therapeutic applications and laboratory services.
"Dr. Chellani adds outstanding experience that will greatly benefit us,”
said Dr. Kevin Krenitsky, President, Enzo Clinical Labs. "We are on
target at the Labs to not only capitalize on our progress in quality
improvement, but also to further our growth strategy to broaden our
capabilities in molecular diagnostics and other new dynamic, esoteric
tests in line with today’s advances in medicine. Dr. Chellani is an
important addition to our team, and we are pleased to have him join us.”
Dr. Chellani, with over 15 years experience in the clinical laboratory
business, most recently was Head of Science and Innovation Portfolio
Development at Quest Diagnostics. Among his responsibilities were
growing Quest’s esoteric testing business, introducing assays and
regionalized tests, and directing product development collaborations
with academic and industry partners. Previously, Dr. Chellani served as
a Senior Scientist in molecular immunology at Abbott Laboratories, head
of Molecular Biology at PerSeptive Diagnostics, director of business
development for biocalorimetric assays at MicroCal Inc., and Program
Director, Biomics, at Perkin Elmer Life Sciences.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and
licensing of innovative health care products and technologies based on
molecular biology and genetic engineering techniques, and in providing
diagnostic services to the medical community. Enzo’s Life Sciences
division develops, produces and markets proprietary labeling and
detection products for gene sequencing, genetic analysis and
immunological research among others. Its catalog of over 40,000 products
serves the molecular biology, drug discovery and pathology research
markets. The Company's therapeutic division is in various stages of
clinical evaluation of its proprietary immune regulation medicines for
uveitis and Crohn's disease and conducts pre-clinical research on
several candidate compounds aimed at producing new mineral and organic
bone, including technology that could provide therapy for osteoporosis
and fractures, among other applications. Enzo’s Clinical Labs division
provides routine and esoteric reference laboratory services for
physicians in the New York Metropolitan and New Jersey areas.
Underpinning the Company’s technology and operations is an extensive
intellectual property estate in which Enzo owns or licenses over 230
patents worldwide, and has pending applications for over 200 more. For
more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
